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Conclusions: The HPV infection in Germany was lower than 
expected. Also in our investigation it appears that HPV positive 
patients have a better clinical outcome than HPV negative 
patients. 
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Introduction: Sinonasal undifferentiated carcinoma (SNUC) is a 
rare aggressive neoplasm arising in the nasal cavity and paranasal 
sinuses. Although intracranial extension from SNUC is common in 
patients with locally advance disease, distant central nervous 
system metastasis from SNUC is an extremely rare occurrence.  
Methods and Materials:  Herein, we present a case, and review 
the limited literature on overall management and outcomes of 
patients with SNUC and management and outcomes of patients 
with SNUC with brain metastases. 
Results:  We report a case of an 80 year old man who presented 
with a locally advanced SNUC involving ethmoid, sphenoid and 
maxillary sinuses and bilateral lymph nodes from level I-V, 
cT4N2cM0. Given his age and the initial extent of his primary 
tumour, he was treated with neo-adjuvant chemotherapy 
followed by palliative chemoradiation with a split course of 50 
Gy in 40 fractions delivered twice a day. Four months after his 
treatments, he developed a recurrence at the left lower eyelid 
and left frontal sinus, intra-abdominal metastases and a left 
cerebellar metastasis. A single fraction of 22 Gy was delivered to 
the cerebellar lesion using stereotactic radiosurgery.  
Upon review of the literature, we found only two cases reported 
of brain metastases that were not due to local intracranial 
extension from the original mass, in which detailed treatment 
information was reported. One patient with partially controlled 
local disease had a left temporoparietal lesion treated with a 
combination of bone marrow transplant and CAV chemotherapy 
and had a partial response. This patient died of disease at 8 
months. The second case was treated initially with surgical 
resection and post-operative chemotherapy and radiation and 
lived for at least another two years while developing further 
metastases- at the time of the printed manuscript the patient 
was still alive.  
Conclusions:  We advocate that aggressive treatment of 
advanced SNUC may be pursued in selected patients. We suggest 
a registry for rare head and neck cancers such as SNUC to help 
guide treatment. 
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Purpose: Stereotactic body radiation therapy (SBRT) has become 
the standard therapy for inoperable early stage non-small cell 
lung cancer (NSCLC) and is increasingly more accepted as an 
alternative to surgery in operable patients. Despite the 
widespread use of SBRT in early stage NSCLC, the ideal dose 
fractionation for treating peripheral lesions is yet to be 
identified. Our institution has pioneered the use of 48 Gy in 3 
fractions as an SBRT dose fractionation schedule. We sought to 
evaluate the efficacy and toxicity associated with this regimen, 
in comparison to outcomes of patients treated at our institution 
with other commonly used SBRT dose regimens.  
Methods and Materials: We retrospectively reviewed the 
medical charts and radiation oncology records of consecutive 
patient with inoperable early stage NSCLC (T1-2 N0 M0) treated 
with SBRT at our institution between May 2010 and March 2015. 
Demographic patient data and dosimetric data regarding SBRT 
treatments were collected. Local/regional control, distant 
failure and overall survival were analyzed. Acute toxicity 
(defined as toxicity<90 days) and late toxicity (defined as 
toxicity>= 90 days) were also reported and graded as per 
standardized Common Terminology Criteria for Adverse Events 
(CTCAE) v4.0. 
Results: A total of 179 consecutive patients with a median age 
of 74.5 years were included. Ninety-eight patients with 110 
lesions received an SBRT dose of 48 Gy in 3 fractions over 5 - 7 
days (Group 1). Eighty one patients with 86 lesions (Group 2) 
received other standard SBRT fractionation schemes (25- 60 Gy 
in 1 – 5 fractions). After a median follow of 20 months (range 6 – 
95), 63% of patients treated with 48 Gy in 3 were alive. The crude 
rates of local, regional and distant failures in groups 1 and 2 were 
12.7%, 9.1%, 15.5% and 22.1%, 17.4% and 23.5%, respectively. 
The odds ratio for local failure, regional failure and distant 
metastasis were 0.5, 0.5 and 0.6 respectively in favour of the 48 
Gy in 3 dose fractionation. There were no cases of SBRT related 
Grade 3 or higher acute or late toxicity.  
Conclusions: The use of SBRT 48 Gy in 3 fractions for peripheral 
early stage NSCLC is associated with excellent outcomes and 
compare favourably with published results of 54 Gy in 3 fractions, 
and 48 Gy in 4 fractions. The favourable toxicity profile 
associated with using 48 Gy in 3 fractions highlights this regimen 
as safe and convenient option for the treatment of peripheral 
lesions in close proximity to the chest wall.  
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Purpose: Lung cancer is the leading cause of cancer-specific 
mortality in North America. Main reason for the high mortality is 
the advanced stage at diagnosis in the majority of patients. Early 
detection of lung cancer by screening high-risk individuals has 
been proposed to improve survival. An effective screening 
program may prevent up to 80% of the deaths from lung cancer. 
We undertook this study to determine if 1H Magnetic Resonance 
Spectroscopy (MRS) of sputum and exhaled breath condensate 
samples can complement and or provide an alternate tool to 
screen and detect lung cancer among high-risk population. 
Methods and Materials: Sputum and Exhaled Breath Condensate 
(EBC) samples were collected from 15 patients. Pathologically 
confirmed non-small cell lung cancer (NSCLC, n = 8), and patients 
with respiratory conditions other than lung cancer (controls, n = 
7) were enrolled. Both sputum and EBC samples were collected 
in thirteen patients; two patients provided EBC samples only. 
Sputum samples were thawed and 250 mL of each sample was 
dispersed in 2M NaCl (prepared in PBS buffer) solution in the ratio 
1:1 (v/v) and vortexed to get homogenous clear suspension; 
frozen EBC samples were thawed and 500 mL neat sample was 
transferred into the NMR tube (with a reusable co-axial capillary 
tube containing standard TSP solution in D2O) for analysis. All 
MRS experiments were performed on a Bruker Avance 400 MHz 
NMR spectrometer at the University of Winnipeg. In order to 
detect metabolite signals, the water signals in both EBC and 
sputum samples were suppressed using PRESAT or excitation 
sculpting pulse sequence. The MRS lab staff was blind to the 
diagnosis until all the samples were analyzed. 
Results: In EBC samples, propionate was detected in 43% of the 
patients in both groups; with similar median concentration of the 
metabolite. Ethanol and acetate were detected in all patients, 
with relatively higher median concentration of the metabolites 
in the cancer group. Acetone and formate were detected in 75% 
and 50% of the cancer group and 43% and 57% of the control 
group, with higher median concentration of the metabolites in 
cancer group. Methanol was detected in 75% and 100% of the 
cancer and control group respectively, with median lower 
